[12] Patent
[11] Patent No.:GC0011446  
[45] Date of Publishing the Grant of the Patent: 31/Oct /2020                75/2020  
Number of the Decision to Grant the Patent:2020/173931
Date of the Decision to Grant the Patent:13/Oct/2020

[21] Application No.:GC 2012-21744

[22] Filing Date:11/7/2012

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
12/7/2011
61/506,737

[72] Inventors:1- Stephen CONNOLLY،2- Mark Richard EBDEN،3- Thomas LANGER،4- Alan Robert STEVEN،5- Craig Robert STEWART،6- Paula Margaret TOMLIN،7- Iain Alastair Stewart WALTERS،8- Andrew John WILLIAMS

[73] Owner: AstraZeneca AB, SE-151 85 , S?dert?lje, Sweden

[74] Agent: Suleiman I. Al-Ammar Law Office

  

 

  

[51]IPC:
C07D403/12, C07D205/04, A61K31/506, C07D317/20, C07D317/24, C07C69/92

[56] Cited Documents:

-WO2006024823 A1 (ASTRAZENECA AB [SE]; ASTRAZENECA UK
LTD [GB]; CHESHIRE DAVID RANULF G) 9 Mrach 2006 Y -US2010016275 A1 (MEGHANI PREMJI [GB], et al) 21 January 2010

- WO2004011443 A1 (ASTRAZENECA AB [SE]; ET AL) 5 February 2004
- WO2004018435 (A1) (ASTRAZENECA AB [SE]; ET AL) 4 March 2004
 
Examiner: PH. Abrar AlSaleem

[54] N-6-2R,3S-3,4-DIHYDROXYBUTAN-2-YLOXY-2-4-FLUOROBENZYLTHIOPYRIMIDIN-4-YL-3-METHYLAZETIDINE-1-SULFONAMIDE AND PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF
[57] Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
No. of claims: 9     No. of figures: 2


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.